Sun Pharmaceutical Industries Ltd announced that its Baska manufacturing facility has been classified as Official Action ...

GLP-1 weight loss drugs are proving beneficial for people struggling with obesity and diabetes, but there is another surprising side effect coming to light.

U.S. drug maker Eli Lilly & Co. is slashing the prices of its popular diabetes and weight-loss drugs Mounjaro and Zepbound by ...

We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. On December 15, 2025, UBS reaffirmed its ...

Judges allow consolidation of vision loss lawsuits filed against Novo Nordisk and Eli Lilly over diabetes and weight loss ...

The investment narrative surrounding Novo Nordisk is undergoing a significant shift. After years of soaring expectations fueled by its obesity and diabetes t ...

Market sentiment has visibly soured. Year-to-date, the share price is down approximately 52%, and it has declined nearly 60% over a twelve-month period. The stock is trading close to its 52-week low, ...

Shares have corrected 55.8 per cent from their high earlier this year of $423.32 to $187.01 based on the Dec. 11 closing ...

The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has granted approval to Novo ...

New obesity treatments such as 'oral Mounjaro' and 'high-dose Wegovy' are scheduled to be released next year. The U.S. Food ...

Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...

As physicians across specialties encounter increasing patient interest in GLP-1 receptor agonists, it is important for them ...